| David J Bilstrom, MD | |
|
98 Poplar St, Blackfoot, ID 83221-1758 | |
| (208) 782-2444 | |
| (208) 785-3115 |
| Full Name | David J Bilstrom |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 37 Years |
| Location | 98 Poplar St, Blackfoot, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972599132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | F39490 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bingham Memorial Hospital | Blackfoot, ID | Hospital |
| Portneuf Medical Center | Pocatello, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bmh Inc | 8426149758 | 124 |
News Archive
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).
UK-based charity, Parkinson's UK is set to provide more than $1million in funding to US biotech company, Neurolixis, to accelerate the development of a promising new drug for people with Parkinson's.
Training people to avoid falls by repeatedly exposing them to unstable situations in the laboratory helped them to later maintain their balance on a slippery floor, according to new research from the Journal of Neurophysiology.
Patients rehospitalized with complications after major surgery are 26% more likely to survive if they return to the hospital where they had their operation compared to those readmitted to a different hospital, according to a national study involving over 9 million Medicare patients in the USA, published in The Lancet.
› Verified 8 days ago
| Entity Name | Bmh Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1982805271 PECOS PAC ID: 8426149758 Enrollment ID: O20070801000213 |
News Archive
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).
UK-based charity, Parkinson's UK is set to provide more than $1million in funding to US biotech company, Neurolixis, to accelerate the development of a promising new drug for people with Parkinson's.
Training people to avoid falls by repeatedly exposing them to unstable situations in the laboratory helped them to later maintain their balance on a slippery floor, according to new research from the Journal of Neurophysiology.
Patients rehospitalized with complications after major surgery are 26% more likely to survive if they return to the hospital where they had their operation compared to those readmitted to a different hospital, according to a national study involving over 9 million Medicare patients in the USA, published in The Lancet.
› Verified 8 days ago
| Entity Name | Bmh Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255539193 PECOS PAC ID: 8426149758 Enrollment ID: O20071018000897 |
News Archive
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).
UK-based charity, Parkinson's UK is set to provide more than $1million in funding to US biotech company, Neurolixis, to accelerate the development of a promising new drug for people with Parkinson's.
Training people to avoid falls by repeatedly exposing them to unstable situations in the laboratory helped them to later maintain their balance on a slippery floor, according to new research from the Journal of Neurophysiology.
Patients rehospitalized with complications after major surgery are 26% more likely to survive if they return to the hospital where they had their operation compared to those readmitted to a different hospital, according to a national study involving over 9 million Medicare patients in the USA, published in The Lancet.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David J Bilstrom, MD 98 Poplar St, Blackfoot, ID 83221-1758 Ph: (208) 782-2444 | David J Bilstrom, MD 98 Poplar St, Blackfoot, ID 83221-1758 Ph: (208) 782-2444 |
News Archive
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).
UK-based charity, Parkinson's UK is set to provide more than $1million in funding to US biotech company, Neurolixis, to accelerate the development of a promising new drug for people with Parkinson's.
Training people to avoid falls by repeatedly exposing them to unstable situations in the laboratory helped them to later maintain their balance on a slippery floor, according to new research from the Journal of Neurophysiology.
Patients rehospitalized with complications after major surgery are 26% more likely to survive if they return to the hospital where they had their operation compared to those readmitted to a different hospital, according to a national study involving over 9 million Medicare patients in the USA, published in The Lancet.
› Verified 8 days ago
Amber Valene Hawker, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 285 W Francis St, Blackfoot, ID 83221 Phone: 208-785-0123 |